Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$7.65 +2.5%	$7.96	$6.10 ▼ $28.67	$529.79M	1.44	258,752 shs	256,013 shs
KROS Keros Therapeutics	$13.73 +2.8%	$14.03	$9.12 ▼ $72.37	$557.64M	1.33	424,324 shs	716,794 shs
NKTX Nkarta	$1.98 -1.5%	$1.90	$1.31 ▼ $6.63	$140.50M	0.72	583,655 shs	349,055 shs
TYRA Tyra Biosciences	$10.45 -2.8%	$10.27	$6.42 ▼ $29.60	$554.79M	1.08	216,807 shs	159,842 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	0.00%	-4.26%	-5.44%	-8.27%	-66.08%
KROS Keros Therapeutics	0.00%	-4.12%	-5.11%	+0.59%	-69.76%
NKTX Nkarta	0.00%	-6.60%	+10.00%	+1.80%	-61.85%
TYRA Tyra Biosciences	0.00%	+0.77%	+2.05%	+3.57%	-46.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCYC Bicycle Therapeutics	3.4309 of 5 stars	3.3	4.0	2.4	4.2	0.6
KROS Keros Therapeutics	2.675 of 5 stars	3.3	2.0	2.5	3.3	0.6
NKTX Nkarta	1.502 of 5 stars	3.6	0.0	1.1	1.7	0.6
TYRA Tyra Biosciences	1.9059 of 5 stars	3.5	0.0	2.4	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.67	Moderate Buy	$21.25	177.78% Upside
KROS Keros Therapeutics	2.50	Moderate Buy	$30.00	118.50% Upside
NKTX Nkarta	3.13	Buy	$14.33	623.91% Upside
TYRA Tyra Biosciences	3.00	Buy	$30.83	195.06% Upside

Current Analyst Ratings Breakdown

Latest NKTX, BCYC, KROS, and TYRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $20.00
7/17/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $25.00
7/1/2025	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/10/2025	KROS Keros Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$32.00 ➝ $18.00
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
5/30/2025	KROS Keros Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$15.00
5/21/2025	TYRA Tyra Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$33.00
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/12/2025	KROS Keros Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$41.00 ➝ $26.00

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$35.28M	15.02	N/A	N/A	$11.48 per share	0.67
KROS Keros Therapeutics	$3.55M	157.10	N/A	N/A	$17.40 per share	0.79
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.78 per share	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$6.78 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$169.03M	-$3.14	N/A	N/A	N/A	-790.07%	-25.54%	-21.23%	N/A
KROS Keros Therapeutics	-$187.35M	-$0.18	44.29	N/A	2.48	8.06%	2.96%	2.74%	N/A
NKTX Nkarta	-$108.79M	-$1.51	N/A	N/A	N/A	N/A	-26.64%	-21.62%	8/12/2025 (Estimated)
TYRA Tyra Biosciences	-$86.48M	-$1.63	N/A	N/A	N/A	N/A	-26.90%	-25.54%	N/A

Latest NKTX, BCYC, KROS, and TYRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	NKTX Nkarta	-$0.37	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	BCYC Bicycle Therapeutics	-$0.95	-$1.14	-$0.19	-$1.14	$9.43 million	$2.90 million
8/6/2025	Q2 2025	KROS Keros Therapeutics	-$1.14	-$0.76	+$0.38	-$0.76	$3.83 million	$0.02 million
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	14.86	14.86
KROS Keros Therapeutics	N/A	21.11	19.29
NKTX Nkarta	N/A	14.48	14.48
TYRA Tyra Biosciences	N/A	22.78	22.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
KROS Keros Therapeutics	71.56%
NKTX Nkarta	80.54%
TYRA Tyra Biosciences	84.14%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	22.90%
KROS Keros Therapeutics	20.60%
NKTX Nkarta	8.40%
TYRA Tyra Biosciences	15.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	53.40 million	Optionable
KROS Keros Therapeutics	100	40.62 million	32.25 million	Optionable
NKTX Nkarta	140	70.96 million	65.00 million	Optionable
TYRA Tyra Biosciences	20	53.09 million	45.02 million	Optionable

NKTX, BCYC, KROS, and TYRA Headlines

Recent News About These Companies

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

August 7 at 10:21 AM | uk.finance.yahoo.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Sees Significant Growth in Short Interest

August 2, 2025 | marketbeat.com

Tyra Biosciences (TYRA) to Release Quarterly Earnings on Wednesday

July 31, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of "Buy" by Brokerages

July 26, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Trading Down 3% - Here's Why

July 23, 2025 | marketbeat.com

Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series

July 21, 2025 | prnewswire.com

Tyra Biosciences (NASDAQ:TYRA) Trading Up 5.7% - Should You Buy?

July 16, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 4.9% - What's Next?

July 15, 2025 | marketbeat.com

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - Morningstar

July 9, 2025 | morningstar.comM

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025

July 8, 2025 | prnewswire.com

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) - FinanzNachrichten.de

July 2, 2025 | finanznachrichten.de

TYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBC

July 2, 2025 | targetedonc.comT

Tyra Biosciences begins patient dosing in phase 2 study of TYRA-300 in low-grade intermediate risk non-muscle invasive bladder cancer

July 1, 2025 | pharmabiz.comP

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

June 30, 2025 | prnewswire.com

Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells 9,568 Shares of Stock

June 21, 2025 | insidertrades.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $70,729.32 in Stock

June 17, 2025 | insidertrades.com

Tyra Biosciences to Participate at Upcoming Investor Conferences

May 12, 2025 | prnewswire.com

One Tyra Biosciences Insider Raised Stake By 284% In Previous Year

May 9, 2025 | finance.yahoo.com

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

May 8, 2025 | prnewswire.com

Why Tyra Biosciences, Inc.’s (TYRA) Stock Is Down 5.48%

May 6, 2025 | aaii.comA

Tyra Biosciences price target lowered to $28 from $29 at BofA

March 30, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX, BCYC, KROS, and TYRA Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$7.65 +0.19 (+2.55%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$7.64 -0.01 (-0.13%)

As of 08/8/2025 04:10 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Keros Therapeutics NASDAQ:KROS

$13.73 +0.37 (+2.77%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$13.38 -0.35 (-2.55%)

As of 08/8/2025 07:00 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Nkarta NASDAQ:NKTX

$1.98 -0.03 (-1.49%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$1.99 +0.01 (+0.51%)

As of 08/8/2025 07:56 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Tyra Biosciences NASDAQ:TYRA

$10.45 -0.30 (-2.79%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$10.44 -0.01 (-0.10%)

As of 08/8/2025 04:30 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time